Drug Trial Radar · NCT06893887
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
May 22, 2025
Primary completion
Dec 15, 2027
Study completion Dec 15, 2028
Sponsor
- Lead sponsor
- Nanjing Tianyinshan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 25, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy. Based on different patterns of disease progression, patients will receive relevant systemic treatments, either with or without local interventional therapy. The primary endpoint is progression-free survival (PFS), while secondary endpoints include overall survival (OS), 1-year OS rate, objective response rate (ORR), disease control rate (DCR), duration of remission (DOR), and safety. Additionally, the study will explore the correlation between patients' clinical pathological characteristics, serum biomarkers, and clinical efficacy.
Conditions
- Hepatocellular Carcinoma(HCC)
Interventions
FOLFOX4Drug
FOLFOX4 was administered by oxaliplatin 85 mg/m² d1+ leucovorin 200 mg/m² d1-2+ fluorouracil 400 mg/m² 2 h→ 600 mg/m² 24 h d1-2 q2w, with a total of 4 cycles
AdebrelimabDrug
Adebrelimab 1200mg, intravenous infusion, every 3 weeks
ApatinibDrug
Apatinib 250mg, oral, once daily.
IcaritinDrug
Epimedium extract soft capsules 2.4g, oral, 2 times daily.
Retlirafusp alfaDrug
Retlirafusp alfa,1800mg, intravenous infusion, every 3 weeks, use for up to 2 years at most.
QL1706Drug
QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.
BevacizumabDrug
Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks.
HAICProcedure
Hepatic Arterial Infusion Chemotherapy
The original treatment regimenDrug
Continue the original targeted therapy combined with immunotherapy. dosage, dosage form,frequency of administration was the same as before.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS(Progression-free Survival)Time frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China Pharmaceutical University Affiliated Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.